India vaccination

New Delhi : The Union Health Minister Harsh Vardhan on Wednesday (March 3, 2021) announced that the people can now take the COVID-19 vaccine shot round the clock as per their convenience. Harsh Vardhan took to his official Twitter account to announce the news and said, "The government has ended the time constraint to increase the speed of vaccination. Citizens of the country can now get vaccinated 24x7 at their convenience." Vardhan who took the vaccine jab on Tuesday added that Prime Minister Narendra Modi understands the health of citizens of the country as well as the value of their time. Earlier on Tuesday, Rajesh Bhushan, Union Health Secretary chaired a high-level review meeting with Additional Chief Secretaries, Principal Secretaries and Secretaries (H&FW) of States and UTs. They reviewed the status and pace of the next phase of the country-wide COVID vaccination program which commenced from March 1. They were urged to utilise 100% capacities of all ... » Learn More about Good news! Now take COVID-19 vaccine shot 24X7 as per your convenience

Karnataka Agriculture Minister B C Patil on Tuesday courted controversy after taking COVID-19 vaccine at his home instead of going to designated hospital, drawing criticism from Health Minister K Sudhakar and others. IMAGE: Karnataka Agriculture Minister B C Patil being administered with the COVID-19 vaccine at his Hirekerur residence in Haveri district. Photograph: Kind courtesy @bcpatilkourava/Twitter Patil, 64, and his wife took the vaccine at his Hirekerur residence in Haveri district, on the second day of the vaccination drive to cover people aged above 60 and 45 plus with co-morbidities. Patil tweeted, 'Took the #COVID19Vaccine with my wife, at my Hirekerur house from the Govt. doctors today. While 'Made In India' vaccines are being immensely appreciated by many countries, some vested interest groups are spreading false information about the vaccines.' As several social media users questioned his decision to take the vaccine at home, Sudhakar said the ... » Learn More about Karnataka minister takes vaccine at home, triggers controversy

(This story was first published in the Times Of India on March 3, 2021) Bhiwandi: A 40-year-old healthcare worker died shortly after getting the second dose of the Covid vaccine in the Bhagya Nagar area of Bhiwandi on Tuesday. Sukhdev Kirdat worked as a driver with an eye specialist in Bhiwandi. His wife Sonali has demanded a probe into whether he died due to the vaccine. central government data. Health ministry officials pointed out deaths account for 0.0004% of the vaccinations. READ: Mumbai City Updates Sukhdev, who got his first shot on January 28, took the second dose at 11am. “He was kept in an observation room, where he fell unconscious after 15 minutes,” said a health official of the civic body. He was rushed to hospital and declared dead on arrival. Sukhdev was under hypertension treatment for three years. “Our doctor checked his blood pressure, which was normal,” said Dr K R Kharat, health officer. Sukhdev, who has two children, was ... » Learn More about Bhiwandi: Healthcare worker dies minutes after second COVID vaccine dose

#Corona Vaccine COVID-19 recovered people showing faster antibody response to Covishield vaccine #Corona Vaccine Get a dose 24x7 at your convenience: Govt removes time constraint for getting Covid-19 shot #Corona Vaccine Coronavirus cases: India records 14,989 new COVID-19 cases, 98 fresh fatalities in past 24 hours #Corona Vaccine List of side effects of Covishield and Covaxin #Corona Vaccine Centre allows states to take call on converting more private hospitals into vaccine sites #Corona Vaccine TMC writes to EC over PM Modi’s photo on Covid-19 vaccination doc For Quick Alerts Subscribe Now India-made Covaxin showed 81% interim efficacy: Bharat Biotech on Phase 3 results View Sample For Quick Alerts ALLOW NOTIFICATIONS For Daily Alerts Just In 6 min ago Jan Sangh founded by Bengal's son, still Mamata calls BJP 'outsider party': Nitin Gadkari ... » Learn More about India-made Covaxin showed 81% interim efficacy: Bharat Biotech on Phase 3 results

#Corona Vaccine India-made Covaxin showed 81% interim efficacy: Bharat Biotech on Phase 3 results #Corona Vaccine Get a dose 24x7 at your convenience: Govt removes time constraint for getting Covid-19 shot #Corona Vaccine Coronavirus cases: India records 14,989 new COVID-19 cases, 98 fresh fatalities in past 24 hours #Corona Vaccine List of side effects of Covishield and Covaxin #Corona Vaccine Centre allows states to take call on converting more private hospitals into vaccine sites #Corona Vaccine TMC writes to EC over PM Modi’s photo on Covid-19 vaccination doc For Quick Alerts Subscribe Now India-made Covaxin showed 81% interim efficacy: Bharat Biotech on Phase 3 results View Sample For Quick Alerts ALLOW NOTIFICATIONS For Daily Alerts Just In 6 min ago Jan Sangh founded by Bengal's son, still Mamata calls BJP 'outsider party': Nitin Gadkari ... » Learn More about COVID-19 recovered people showing faster antibody response to Covishield vaccine

India-made COVID-19 vaccine Covaxin has demonstrated an interim clinical efficacy of 81% in its Phase 3 clinical trial, vaccine maker Bharat Biotech said. Covaxin has demonstrated high clinical efficacy trend against COVID-19 as well as significant immunogenicity against the rapidly emerging variants, CMD Krishna Ella said. A statement from Bharat Biotech, which developed the vaccine in collaboration with Indian Council of Medical Research (ICMR), said 25,800 participants between 18-98 years of age were enrolled for the Phase 3 study. It included 2,433 over the age of 60 and 4,500 with comorbidities. The first interim analysis is based on 43 cases, of which 36 cases of COVID-19 were observed in the placebo group versus seven cases observed in the Covaxin group, resulting in a point estimate of vaccine efficacy of 80.6%. Also read: Coronavirus | Hyderabad CSIR lab helped develop key molecule for Covaxin The interim analysis included a preliminary review of the safety ... » Learn More about Bharat Biotech says COVID-19 vaccine Covaxin shows 81% efficacy in Phase 3 clinical trials

The Kangra district administration on Wednesday said special provisions will be made to vaccinate the Dalai Lama against COVID-19 after the Dharamsala-based Central Tibetan Administration (CTA) wrote to the Indian government about this. The CTA, also known as the Tibetan government-in-exile, had asked the Centre and the Kangra district medical officer to vaccinate the Dalai Lama and those working around him at the earliest, its secretary of health Palden said. "We have also requested for vaccination of the whole Tibetan community living in India," he added. When contacted, Kangra Deputy Commissioner Rakesh Prajapati said no special permission is required for this, and added, "Everyone above 60 will be vaccinated. For His Holiness the Dalai Lama, we will make special provisions." Earlier, Kangra Chief Medical Officer Gurdarshan Gupta said the request by the CTA for vaccination of the Dalai Lama and the people living around him was sent to the government. "Permission has come ... » Learn More about Modalities being worked out for Dalai Lama’s COVID-19 vaccination: Kangra authorities

With India’s daily new Covid-19 infections slowing and the vaccination drive gaining pace, analysts are betting on a stronger rebound in the economy and corporate profits in the months ahead. Robust, better-than-expected third-quarter results have given a big fillip to India Inc . The markets now need just one thing to keep rising --- earnings . And the Street sees them rising, with major brokerages upgrading earnings estimates for FY21-23 for major firms. Cyclical rebound Materials have seen the biggest average earnings growth among sectors in the latest quarter, boosted by JSW Steel’s profit and sales surge. Strong loan growth at banks such as HDFC Bank saw most of them beat estimates, even as they continued to set aside more money for bad loans. This year, “forward earnings will grow much faster than market appreciation, so the PE multiples will come off," Neelkanth Mishra, India strategist at Credit Suisse, said in a podcast. Earnings estimates will keep ... » Learn More about India Inc set for major earnings bonanza next fiscal

#United Kingdom UK won't issue 'immunity' COVID-19 passports #United Kingdom India extends restrictions on flights to UK till February 14 due to new variant of Covid-19 #United Kingdom For India, Pakistan to find lasting resolution in Kashmir, says UK #United Kingdom UK govt hails India’s religious diversity, inclusive tradition in Parliament debate #United Kingdom UK govt rolls out 'Act like you’ve got it' drive amid 'alarming' COVID-19 spike #United Kingdom New UK strain of COVID-19 hits 90 Indians For Quick Alerts Subscribe Now Sasikala, expelled AIADMK chief, quits politics ahead of Tamil Nadu polls View Sample For Quick Alerts ALLOW NOTIFICATIONS For Daily Alerts Just In 46 min ago Use of PM's photo in petrol pump hoardings violates poll code, should be removed: ECI 47 min ago Sasikala, expelled AIADMK chief, quits politics ahead of ... » Learn More about UK MPs to debate press freedom, safety of protesters in India next week

Bharat Biotech 's homegrown Covid-19 vaccine has shown an interim vaccine efficacy of 81% in late-stage clinical trials, the Indian company said on Wednesday. The interim analysis was based on 43 recorded cases of Covid-19 in the trial of 25,800 participants, conducted in partnership with the Indian government's medical research body. Thirty-six of the 43 cases were recorded in participants who received a placebo, compared with seven cases in people who were given the Bharat Biotech vaccine , pointing to an efficacy rate of 80.6%, the company said. India had approved the vaccine, branded COVAXIN, in January without late-stage efficacy data, raising questions about its effectiveness. India's vaccination drive, currently underway, includes COVAXIN and a vaccine developed by Oxford University and AstraZeneca. Earlier this week, Indian Prime Minister Narendra Modi was inoculated with the first dose of COVAXIN. ... » Learn More about Bharat Biotech says Covid-19 vaccine shows 81% interim efficacy